New Drug Offers Hope for Relapsed Neuroblastoma in Children
Australian researchers have discovered that romidepsin, an approved lymphoma drug, can effectively combat treatment-resistant neuroblastoma in children. This combination therapy bypasses resistant pathways typically found in relapsed tumors, significantly reducing tumor growth and extending survival. The study emphasizes the potential of romidepsin to improve outcomes in pediatric oncology, while further clinical trials are necessary to confirm its safety and efficacy.